Supplementary Protocol from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (atezolizumab) and VEGF (bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma Kanwal Raghav , Suyu Liu , Michael J. Overman , Anneleis F. Willett , Mark Knafl , Szu-Chin Fu , Anais Malpica , Seema Prasad , Richard E. Royal , Christopher P. Scally , Paul F. Mansfield , Ignacio I. Wistuba , Andrew P. Futreal , Dipen M. Maru , Luisa M. Solis Soto , Edwin R. Parra Cuentas , Honglei Chen , Pamela Villalobos , Anuj Verma , Armeen Mahvash , Patrick Hwu , Patricia Cortazar , Edward McKenna , Cindy Yun , Shannon Dervin , Katja Schulze , Walter C. Darbonne , Ajaykumar C. Morani , Scott Kopetz , Keith F. Fournier , Scott E. Woodman , James C. Yao , Gauri R. Varadhachary , Daniel M. Halperin openalex（2023）
Key words
Malignant Pleural Mesothelioma, Peritoneal Surface Malignancy, Peritoneal Metastases
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
